Loading…
Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
80pct
90d open
vs 6,526 other HR bills in the 114th — cohort avg 56d
Ensuring Patient Access and Effective Drug Enforcement Act of 2015 (Sec. 2) Amends the Controlled Substances Act to define: (1) "factors as may be relevant to and consistent with the public health and safety," for purposes of the Attorney General's determination of whether registering an applicant to manufacture or distribute a controlled substance in schedule I or II is in the public interest, as factors that are relevant to and consistent with the findings of such Act; and (2) "imminent danger to the public health or safety," for purposes of the suspension of such a registration, to mean that in the absence of an immediate suspension order, controlled substances will continue to be distributed or dispensed by a registrant who knows or should know through fulfilling the obligations of the registrant under this Act that the dispensing is outside the usual course of professional practice, the distribution or dispensing poses a present or foreseeable risk of adverse health consequences or death due to the abuse or misuse of the controlled substances, or the controlled substances will continue to be diverted outside of legitimate distribution channels. Requires an order to show cause as to why such a registration should not be denied, revoked, or suspended to: (1) contain a statement of the basis for the denial, revocation, or suspension, including specific citations to any laws or regulations alleged to be violated; (2) direct the applicant or registrant to appear before the Attorney General at a specific place and time within 30 days after receipt of the order; and (3) notify the applicant or registrant of the opportunity to submit a corrective action plan on or before such appearance. Requires the Attorney General, upon review of any such plan, to determine whether denial, revocation, or suspension proceedings should be discontinued or deferred for purposes of modifications to such plan. Makes such requirements inapplicable to the issuance of an immediate suspension order. (Sec. 3) Directs the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs and the Director of the Centers for Disease Control and Prevention, to submit a report identifying: (1) obstacles to legitimate patient access to controlled substances; (2) issues with diversion of controlled substances; and (3) how collaboration between federal, state, local, and tribal law enforcement agencies and the pharmaceutical industry can benefit patients and prevent diversion and abuse of controlled substances.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (29)
Received in the Senate and Read twice and referred to the Committee on the Judiciary.
Motion to reconsider laid on the table Agreed to without objection.
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H2329)
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H2329)
DEBATE - The House proceeded with forty minutes of debate on H.R. 471.
Considered under suspension of the rules. (consideration: CR H2329-2332)
Mrs. Blackburn moved to suspend the rules and pass the bill, as amended.
Placed on the Union Calendar, Calendar No. 63.
Committee on the Judiciary discharged.
Committee on the Judiciary discharged.
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2016 · fourth_quarter · Health Issues
H.R. 471/S. 483, Ensuring Patient Access and Effective Drug Enforcement Act of 2015. Implementation issues related to the Patient Protection and Affordable Care Act (P.L. 111-148), the Medicare Access and CHIP Reauthorization Act (P.L. 114-10), and the Comprehensive Addiction and Recovery Act (P.L. 114-198). H.R. 34, 21st Century Cures Act. S. 524/H.R. 953, Comprehensive Addiction and Recovery Act (CARA). S. 2943, National Defense Authorization Act, FY 2017, healthcare provisions.
Client expense: $210,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2016 · fourth_quarter · Alcohol and Drug Abuse
H.R.471-Ensuring Patient Access and Effective Drug Enforcement Act of 2015 H.R.953-Comprehensive Addiction and Recovery Act of 2015 H.R.1641-Jason Simcakoski Memorial Opioid Safety Act H.R.1725-National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015 H.R.1821-Opioid Overdose Reduction Act of 2015 H.R.2298-Medicare Patient Safety and Drug Abuse Prevention Act H.R.2463-Dispose Responsibly of your Pills (DROP) Act of 2015 H.R.2536-Recovery Enhancement for Addiction Treatment (TREAT) Act H.R.2805-Heroin and Prescription Opioid Abuse Prevention, Education, and Enforcement Act of 2015 H.R.2850-Stop Overdose Stat Act of 2015 H.R.2872-Opioid Addiction Treatment Modernization Act H.R.3014-Medical Controlled Substances Transportation Act of 2015 H.R.3250-DXM Abuse Prevention Act of 2015 H.R.3537-Synthetic Drug Control Act of 2015 H.R.3677-Opioid Abuse Prevention and Treatment Act of 2015 H.R.3680-Co-Prescribing to Reduce Overdose Act of 2015 H.R.3691-Improving Treatment for Pregnant and Postpartum Women Act of 2015 H.R.3865-Cradle Act H.R.4063-Promoting Responsible Opioid Management and Incorporating Scientific Expertise Act H.R.4447-Opioid and Heroin Epidemic Emergency Supplemental Appropriations Act H.R.4499-Promoting Responsible Opioid Prescribing Act of 2016 H.R.4599-Reducing Unused Medications Act of 2016 H.R.4641-To provide for the establishment of an inter-agency task force to review, modify, and update best practices for pain management and prescribing pain medication, and for other purposes. H.R.4697-Prevevent Drug Addiction Act of 2016 S.36-Protecting Our Youth from Dangerous Synthetic Drugs Act of 2015 S.480-National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015 S.483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015 S.524-Comprehensive Addiction and Recovery Act of 2015 S.636-Increasing the Safety of Prescription Drug Use Act of 2015 S.707-Opioid Overdose Reduction Act of 2015 S.954-FDA Accountability for Public Safety Act S.1134-Heroin and Prescription Opioid Abuse Prevention, Education, and Enforcement Act of 2015 S.1327-Synthetic Abuse and Labeling of Toxic Substances (SALTS) Act S.1392-Safer Prescribing of Controlled Substances Act S.1410-Treatment and Recovery Investment Act S.1431-Prescription Drug Abuse Prevention and Treatment Act of 2015 S.1455-Recovery Enhancement for Addiction Treatment Act S.1654-Overdose Prevention Act S.1913-Stopping Medication Abuse and Protecting Seniors Act of 2015 S.2256-Co-Prescribing Saves Lives Act of 2015 S.2562-Heroin and Prescription Drug Abuse Prevention and Reduction Act S.2567-Preventing Overprescribing for Pain Act of 2016 S.2578-Reducing Unused Medications Act of 2016 S.2687-Plan of Safe Care Improvement Act
Client expense: $462,139 · Firm income: Not reported
2016 · fourth_quarter · Law Enforcement/Crime/Criminal Justice
H.R.159-Stop Exploitation Through Trafficking Act H.R.181-Justice for Victims of Trafficking Act H.R.246-To improve the response to victims of child sex trafficking H.R.285-Stop Advertising Victims of Exploitation (SAVE) Act H.R.350-Human Trafficking Prevention, Intervention and Recovery Act H.R.357-Human Trafficking Prevention Act H.R.398-Trafficking Awareness Training for Health Care Act H.R.460-Human Trafficking Detection Act H.R.468-Enhancing Services for Runaway and Homeless Victims for Youth Trafficking Act H.R.469-Strengthening Child Welfare Response to Trafficking Act H.R.471-Ensuring Patient Access and Effective Drug Enforcement Act of 2015 H.R.514-Human Trafficking Prioritization Act H.R.515-International Megans Law to Prevent Demand for Child Sex H.R.1854-Comprehensive Justice and Mental Health Act of 2015 H.R.1877-Mental Health First Aid Act of 2015 H.R.3014-Medical Controlled Substances Transportation Act of 2015 H.R.3537-Synthetic Drug Control Act of 2015 H.R.4365-Protecting Patient Access to Emergency Medications Act of 2016 S.178-Justice for Victims of Trafficking Act of 2015 S.483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015 S.529-Combatting Human Trafficking Act of 2015 S.623-Human Trafficking Detection Act of 2015 S.642-Human Trafficking Survivors Relief and Empowerment Act of 2015 S.711-Mental Health First Act of 2015 S.993-Comprehensive Justice and Mental Health Act of 2015 S.1446-SOAR to Health and Wellness Act of 2015 S.2932-Protecting Patient Access to Emergency Medications Act of 2016 P.L.114-324-Justice for All Reauthorization Act
Client expense: $462,139 · Firm income: Not reported
2016 · fourth_quarter · Health Issues
H.R. 471/S. 483, Ensuring Patient Access and Effective Drug Enforcement Act of 2015. Implementation issues related to the Patient Protection and Affordable Care Act (P.L. 111-148), the Medicare Access and CHIP Reauthorization Act (P.L. 114-10), and the Comprehensive Addiction and Recovery Act (P.L. 114-198). H.R. 34, 21st Century Cures Act. S. 524/H.R. 953, Comprehensive Addiction and Recovery Act (CARA). S. 2943, National Defense Authorization Act, FY 2017, healthcare provisions.
Client expense: $180,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2016 · fourth_quarter · Pharmacy
H.R. 471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management, including S. 776 The Medication Therapy Management Empowerment Act of 2015. H.R.5951 and S. 3308, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act.
Client expense: $610,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Reported by the Committee on Energy and Commerce. H. Rept. 114-85, Part I.
Congress.gov source codes: 5000, H12200
Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.
Referred to the Subcommittee on Health.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Congress.gov source codes: H11100, H11100-A
Introduced in House
Congress.gov source codes: 1000, Intro-H
| Referred to |
| January 22, 2015 |
| Energy and Commerce Committee | House | Referred to | January 22, 2015 |
| January 22, 2015 |
| Republican |
| TN |
| Peter Welch | Democratic | VT |
| Ryan A. Costello | Republican | PA |
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Pharmacy
(H.R. 696/S. 506) Medicare Prompt Pay Discount Exclusion,legislation to ensure more appropriate general payment amount for drugs & biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Legislation to exclude cancer drugs from sequestration cuts. HR471/S483 Ensuring Patient Access and Effective Drug Enforcement Act of 2015; Medicare Program Part B Drug Payment Model.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Health Issues
Issues relating to prescription drug abuse. Issues relating to incentives for tamper-resistant formulations. Issues relating to FDA approvals of new drugs and generic drugs. Issues related to the FDA. Issues related to Opioids. Issues relating to Medicare Part D rebates. House 21st Century Cures bill (Senate companion which includes NIH and FDA issues). H.R. 471/S. 483: Ensuring Patient Access and Effective Drug Enforcement Act of 2015. Issues relating to the labeling of generic drugs. Issues relating to CDC guidance for prescribing opioids. S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act. Issues relating to products containing high doses of acetaminophen. Issues relating to the labeling of generic drugs. Issues relating to removal of FDA unapproved products from the market. H.R. 5046: Comprehensive Opioid Abuse Reduction Act of 2016. S.524 - To authorize the Attorney General and Secretary of Health and Human Services to award grants to address the national epidemics of prescription opioid abuse and heroin use, and to provide for the establishment of an inter-agency task force to review, modify, and update best practices for pain management and prescribing pain medication, and for other purposes.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES
2016 · fourth_quarter · Pharmacy
Issues relating to prescription drug abuse (H.R. 471, S.483, S. 524, H.R. 953, H.R. 4641) and pharmaceutical market value
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Pharmacy
Legislation and policies relating to: H.R. 471/S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act H.R. 639 - Improving Regulatory Transparency for New Medical Therapies Act H.R. 953/S. 524 - Comprehensive Addiction and Recovery Act of 2015 H.R. 2536/S. 1455 - Recovery Enhancement for Addiction Treatment (TREAT) Act H.R. 4435 - Comprehensive Behavioral Health Reform and Recovery Act of 2016 H.R. 4843 - Infant Plan of Safe Care Improvement Act H.R. 4978 - NAS Healthy Babies Act H.R. 4981 - Opioid Use Disorder Treatment Expansion and Modernization Act H.R. 5046 - Comprehensive Opioid Abuse Reduction Act of 2016 H.R. 5052 - Opioid Program Evaluation Act S. 1392 - Safe Prescribing of Controlled Substances Act S. 2423 - A bill making appropriations to address the heroin and opioid drug abuse epidemic for the fiscal year ending September 30, 2016, and for other purposes S. 3075 - Addiction Prevention and Responsible Opioid Practices Act S. 3223 - Expanded Access to Treatment and Recovery Act
Client expense: Not reported · Firm income: $23,450
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, Veterans Affairs, Dept of (VA), White House Office
2016 · fourth_quarter · Health Issues
Issues relating to prescription drug abuse. Issues relating to incentives for tamper-resistant formulations. Issues relating to FDA approvals of new drugs and generic drugs. Issues related to the FDA Issues related to Opioids Issues relating to Medicare Part D rebates. House 21st Century Cures bill (Senate companion which includes NIH and FDA issues) H.R.471, S. 483 -Ensuring Patient Access and Effective Drug Enforcement Act of 2015 S. 524 the Comprehensive Addiction and Recovery Act and related legislation H.R. 4641 Issues relating to the labeling of generic drugs. Issues relating to CDC guidance for prescribing opioids S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act Issues relating to products containing high doses of acetaminophen. Issues relating to the labeling of generic drugs. Issues relating to removal of FDA unapproved products from the market HR 5046/S 524 - Opioid abuse legislation H.R.4641 - To provide for the establishment of an inter-agency task force to review, modify, and update best practices for pain management and prescribing pain medication, and for other purposes.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Health Issues
Issues related to prescription drug abuse; issues related to abuse deterrent formulations; issues related to Medicaid rebates; issues related to implementation of the Affordable Care Act; HR.471- Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2016 · fourth_quarter · Health Issues
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation, including H.R. 4641 and H.R. 5046; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to FDA policy, including marketed new drugs without approved NDAs or ANDAs; issues relating to removal of FDA unapproved products from the market such as KCL and Adrenalin; H.R. 5046/S. 524 - Opioid abuse legislation.
Client expense: $410,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Health Issues
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; House 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 -Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation H.R. 4641; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market; and HR 5046/S 524 - Opioid abuse legislation.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Pharmacy
Rx Pedigree (Public Law 113-54); Prescription Drug Monitoring Programs (S. 480, H.R. 1725); Prescription Drug Abuse - General issues related to Rx drug abuse, (H.R. 471, S. 483, S. 524, H.R. 953, H.R. 4641); 21st Century Cures (H.R. 6, H.R. 34); Importation of Prescription Drugs (S. 122, H.R. 2228; Issues related to pharmaceutical market value
Client expense: $268,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2016 · fourth_quarter · Pharmacy
Importation of prescription drugs (S. 122, H.R. 2228) Rx Pedigree (PL 113-54) Prescription Drug Monitoring Programs (S. 480, H.R. 1725) Prescription Drug Abuse - General issues related to Rx drug abuse (H.R. 471, S. 483, S. 524, H.R. 953, H.R. 4641) 21st Century Cures (H.R. 6, H.R. 34)
Client expense: Not reported · Firm income: $80,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Pharmacy
H.R. 471, the Ensuring Patient Access and Effective Drug Enforcement Act of 2015 S.483, The Regulatory Transparency, Patient Access and Effective Drug Enforcement Act
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Alcohol and Drug Abuse
H.R. 471 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015 S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015 S.524 - Comprehensive Addiction and Recovery Act of 2016 H.R.953 - Comprehensive Addiction and Recovery Act of 2015 HR 3250 - DXM Abuse Prevention Act S. 2294 - DXM Abuse Prevention Act H.R. 5046 - Comprehensive Opioid Abuse Reduction Act of 2016 H.R.4931 - Pharmaceutical Stewardship Act of 2016 S. 3075 - Addiction Prevention and Responsible Opioid Practices Act
Client expense: $380,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Alcohol and Drug Abuse
H.R. 471 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; Implementation of Public Law 114-198; S.524 - Comprehensive Addiction and Recovery Act of 2016; H.R.953 - Comprehensive Addiction and Recovery Act of 2015;
Client expense: $245,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), Office of Natl Drug Control Policy (NDCP), Office of Personnel Management (OPM), SENATE
2016 · first_quarter · Health Issues
H.R. 6, 21st Century Cures Act S. 2700, FDA and NIH Workforce Authorities Modernization Act; H.R. 3381, Childhood Cancer STAR Act; Discussions to clarify or reform the 340B program; Biologics Price Competition and Innovation Act; H.R. 1101 & S. 1287, Viral Hepatitis Testing Act; Public Law 111-148, The Patient Protection and Affordable Care Act; H.R. 471 & S. 483, Ensuring Patient Access and Effective Drug Enforcement of 2015; H.R. 1725 & S. 480, National All Schedules Prescription Electronic Reporting Reauthorization of 2015; H.R. 2228 & S.122, Safe and Affordable Drugs from Canada Act of 2015; Proposals to address prescription drug abuse; Implementation of The Prescription Drug User Fee Act (PDUFA); Implementation of The Biosimilars User Fee Act (BsUFA); Public Law 113-54, Drug Quality & Security Act; H.R. 639 & S. 481, Improving Regulatory Transparency for New Medical Therapies; H.R. 2570 & S. 1396, Value-Based Insurance Design Seniors Copayment Reduction Act of 2015; H.R. 3677 Opioid Abuse Prevention and Treatment Act of 2015; S. 524, Comprehensive Addiction and Recovery Act of 2016;
Client expense: $2,610,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), Veterans Affairs, Dept of (VA)
2016 · third_quarter · Health Issues
H.R. 471/S. 483, Ensuring Patient Access and Effective Drug Enforcement Act of 2015. Implementation issues related to the Patient Protection and Affordable Care Act (P.L. 111-148). H.R. 6, 21st Century Cures Act. S. 524/H.R. 953, Comprehensive Addiction and Recovery Act (CARA). H.R. 4909/S. 2814, National Defense Authorization Act, FY 2017, healthcare provisions.
Client expense: $190,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2016 · third_quarter · Health Issues
Issues relating to prescription drug abuse. Issues relating to incentives for tamper-resistant formulations. Issues relating to FDA approvals of new drugs and generic drugs. Issues related to the FDA Issues related to Opioids Issues relating to Medicare Part D rebates. House 21st Century Cures bill (Senate companion which includes NIH and FDA issues) H.R.471, S. 483 -Ensuring Patient Access and Effective Drug Enforcement Act of 2015 S. 524 the Comprehensive Addiction and Recovery Act and related legislation H.R. 4641 Issues relating to the labeling of generic drugs. Issues relating to CDC guidance for prescribing opioids S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act Issues relating to products containing high doses of acetaminophen. Issues relating to the labeling of generic drugs. Issues relating to removal of FDA unapproved products from the market HR 5046/S 524 - Opioid abuse legislation H.R.4641 - To provide for the establishment of an inter-agency task force to review, modify, and update best practices for pain management and prescribing pain medication, and for other purposes.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Pharmacy
H.R. 471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management, including S. 776 The Medication Therapy Management Empowerment Act of 2015. H.R.5951 and S. 3308, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act.
Client expense: $310,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Health Issues
Issues related to prescription drug abuse; issues related to abuse deterrent formulations; issues related to Medicaid rebates; issues related to implementation of the Affordable Care Act; HR.471- Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2016 · third_quarter · Pharmacy
Legislation and policies relating to: H.R. 471/S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act H.R. 639 - Improving Regulatory Transparency for New Medical Therapies Act H.R. 953/S. 524 - Comprehensive Addiction and Recovery Act of 2015 H.R. 2536/S. 1455 - Recovery Enhancement for Addiction Treatment (TREAT) Act H.R. 4435 - Comprehensive Behavioral Health Reform and Recovery Act of 2016 H.R. 4843 - Infant Plan of Safe Care Improvement Act H.R. 4978 - NAS Healthy Babies Act H.R. 4981 - Opioid Use Disorder Treatment Expansion and Modernization Act H.R. 5046 - Comprehensive Opioid Abuse Reduction Act of 2016 H.R. 5052 - Opioid Program Evaluation Act S. 1392 - Safe Prescribing of Controlled Substances Act S. 2423 - A bill making appropriations to address the heroin and opioid drug abuse epidemic for the fiscal year ending September 30, 2016, and for other purposes S. 3075 - Addiction Prevention and Responsible Opioid Practices Act S. 3223 - Expanded Access to Treatment and Recovery Act
Client expense: Not reported · Firm income: $23,450
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, Veterans Affairs, Dept of (VA), White House Office
2016 · second_quarter · Alcohol and Drug Abuse
H.R. 471 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015 S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015 S.524 - Comprehensive Addiction and Recovery Act of 2016 H.R.953 - Comprehensive Addiction and Recovery Act of 2015
Client expense: $580,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Alcohol and Drug Abuse
H.R. 471 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015 S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015 S.524 - Comprehensive Addiction and Recovery Act of 2016 H.R.953 - Comprehensive Addiction and Recovery Act of 2015 HR 3250 - DXM Abuse Prevention Act S. 2294 - DXM Abuse Prevention Act H.R. 5046 - Comprehensive Opioid Abuse Reduction Act of 2016 H.R.4931 - Pharmaceutical Stewardship Act of 2016 S. 3075 - Addiction Prevention and Responsible Opioid Practices Act
Client expense: $920,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Pharmacy
(H.R. 696/S. 506) Medicare Prompt Pay Discount Exclusion,legislation to ensure more appropriate general payment amount for drugs & biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Legislation to exclude cancer drugs from sequestration cuts. HR471/S483 Ensuring Patient Access and Effective Drug Enforcement Act of 2015; Medicare Program Part B Drug Payment Model.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Health Issues
Issues relating to prescription drug abuse. Issues relating to incentives for tamper-resistant formulations. Issues relating to FDA approvals of new drugs and generic drugs. Issues related to the FDA. Issues related to Opioids. Issues relating to Medicare Part D rebates. House 21st Century Cures bill (Senate companion which includes NIH and FDA issues). H.R. 471/S. 483: Ensuring Patient Access and Effective Drug Enforcement Act of 2015. Issues relating to the labeling of generic drugs. Issues relating to CDC guidance for prescribing opioids. S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act. Issues relating to products containing high doses of acetaminophen. Issues relating to the labeling of generic drugs. Issues relating to removal of FDA unapproved products from the market. H.R. 5046: Comprehensive Opioid Abuse Reduction Act of 2016. S.524 - To authorize the Attorney General and Secretary of Health and Human Services to award grants to address the national epidemics of prescription opioid abuse and heroin use, and to provide for the establishment of an inter-agency task force to review, modify, and update best practices for pain management and prescribing pain medication, and for other purposes.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES
2016 · third_quarter · Pharmacy
Issues relating to prescription drug abuse (H.R. 471, S.483, S. 524, H.R. 953, H.R. 4641) and pharmaceutical market value
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Pharmacy
Importation of prescription drugs (S. 122, H.R. 2228) Rx Pedigree (PL 113-54) Prescription Drug Monitoring Programs (S. 480, H.R. 1725) Prescription Drug Abuse - General issues related to Rx drug abuse (H.R. 471, S. 483, S. 524, H.R. 953, H.R. 4641) 21st Century Cures (H.R. 6)
Client expense: Not reported · Firm income: $80,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Pharmacy
Rx Pedigree (Public Law 113-54); Prescription Drug Monitoring Programs (S. 480, H.R. 1725); Prescription Drug Abuse - General issues related to Rx drug abuse, (H.R. 471, S. 483, S. 524, H.R. 953, H.R. 4641); 21st Century Cures (H.R. 6); Importation of Prescription Drugs (S. 122, H.R. 2228; Issues related to pharmaceutical market value
Client expense: $267,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2016 · third_quarter · Health Issues
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation, including H.R. 4641 and H.R. 5046; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market.
Client expense: $290,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Pharmacy
H.R. 471, the Ensuring Patient Access and Effective Drug Enforcement Act of 2015 S.483, The Regulatory Transparency, Patient Access and Effective Drug Enforcement Act
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Health Issues
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; House 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 -Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation H.R. 4641; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market; and HR 5046/S 524 - Opioid abuse legislation.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Alcohol and Drug Abuse
H.R. 471 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; Implementation of Public Law 114-198; S.524 - Comprehensive Addiction and Recovery Act of 2016; H.R.953 - Comprehensive Addiction and Recovery Act of 2015; H.R. 3250 - DXM Abuse Prevention Act; H.R. 5951/S. 3308 - Improving Transparency and Accuracy in Medicare Part D Spending Act
Client expense: $335,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), Office of Natl Drug Control Policy (NDCP), Office of Personnel Management (OPM), SENATE
2016 · third_quarter · Alcohol and Drug Abuse
H.R.471-Ensuring Patient Access and Effective Drug Enforcement Act of 2015 H.R.953-Comprehensive Addiction and Recovery Act of 2015 H.R.1641-Jason Simcakoski Memorial Opioid Safety Act H.R.1725-National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015 H.R.1821-Opioid Overdose Reduction Act of 2015 H.R.2298-Medicare Patient Safety and Drug Abuse Prevention Act H.R.2463-Dispose Responsibly of your Pills (DROP) Act of 2015 H.R.2536-Recovery Enhancement for Addiction Treatment (TREAT) Act H.R.2805-Heroin and Prescription Opioid Abuse Prevention, Education, and Enforcement Act of 2015 H.R.2850-Stop Overdose Stat Act of 2015 H.R.2872-Opioid Addiction Treatment Modernization Act H.R.3014-Medical Controlled Substances Transportation Act of 2015 H.R.3250-DXM Abuse Prevention Act of 2015 H.R.3537-Synthetic Drug Control Act of 2015 H.R.3677-Opioid Abuse Prevention and Treatment Act of 2015 H.R.3680-Co-Prescribing to Reduce Overdose Act of 2015 H.R.3691-Improving Treatment for Pregnant and Postpartum Women Act of 2015 H.R.3865-Cradle Act H.R.4063-Promoting Responsible Opioid Management and Incorporating Scientific Expertise Act H.R.4447-Opioid and Heroin Epidemic Emergency Supplemental Appropriations Act H.R.4499-Promoting Responsible Opioid Prescribing Act of 2016 H.R.4599-Reducing Unused Medications Act of 2016 H.R.4641-To provide for the establishment of an inter-agency task force to review, modify, and update best practices for pain management and prescribing pain medication, and for other purposes. H.R.4697-Prevevent Drug Addiction Act of 2016 S.36-Protecting Our Youth from Dangerous Synthetic Drugs Act of 2015 S.480-National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015 S.483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015 S.524-Comprehensive Addiction and Recovery Act of 2015 S.636-Increasing the Safety of Prescription Drug Use Act of 2015 S.707-Opioid Overdose Reduction Act of 2015 S.954-FDA Accountability for Public Safety Act S.1134-Heroin and Prescription Opioid Abuse Prevention, Education, and Enforcement Act of 2015 S.1327-Synthetic Abuse and Labeling of Toxic Substances (SALTS) Act S.1392-Safer Prescribing of Controlled Substances Act S.1410-Treatment and Recovery Investment Act S.1431-Prescription Drug Abuse Prevention and Treatment Act of 2015 S.1455-Recovery Enhancement for Addiction Treatment Act S.1654-Overdose Prevention Act S.1913-Stopping Medication Abuse and Protecting Seniors Act of 2015 S.2256-Co-Prescribing Saves Lives Act of 2015 S.2562-Heroin and Prescription Drug Abuse Prevention and Reduction Act S.2567-Preventing Overprescribing for Pain Act of 2016 S.2578-Reducing Unused Medications Act of 2016 S.2687-Plan of Safe Care Improvement Act
Client expense: $512,329 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Law Enforcement/Crime/Criminal Justice
H.R.159-Stop Exploitation Through Trafficking Act H.R.181-Justice for Victims of Trafficking Act H.R.246-To improve the response to victims of child sex trafficking H.R.285-Stop Advertising Victims of Exploitation (SAVE) Act H.R.350-Human Trafficking Prevention, Intervention and Recovery Act H.R.357-Human Trafficking Prevention Act H.R.398-Trafficking Awareness Training for Health Care Act H.R.460-Human Trafficking Detection Act H.R.468-Enhancing Services for Runaway and Homeless Victims for Youth Trafficking Act H.R.469-Strengthening Child Welfare Response to Trafficking Act H.R.471-Ensuring Patient Access and Effective Drug Enforcement Act of 2015 H.R.514-Human Trafficking Prioritization Act H.R.515-International Megans Law to Prevent Demand for Child Sex H.R.1854-Comprehensive Justice and Mental Health Act of 2015 H.R.1877-Mental Health First Aid Act of 2015 H.R.3014-Medical Controlled Substances Transportation Act of 2015 H.R.3537-Synthetic Drug Control Act of 2015 H.R.4365-Protecting Patient Access to Emergency Medications Act of 2016 S.178-Justice for Victims of Trafficking Act of 2015 S.483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015 S.529-Combatting Human Trafficking Act of 2015 S.623-Human Trafficking Detection Act of 2015 S.642-Human Trafficking Survivors Relief and Empowerment Act of 2015 S.711-Mental Health First Act of 2015 S.993-Comprehensive Justice and Mental Health Act of 2015 S.1446-SOAR to Health and Wellness Act of 2015 S.2932-Protecting Patient Access to Emergency Medications Act of 2016
Client expense: $512,329 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · first_quarter · Health Issues
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures, and Senate companion bill, issues relating to the FDA and NIH; H.R.471, S. 483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market.
Client expense: $790,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Pharmacy
Legislation and policies relating to: H.R. 471/S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act H.R. 639 - Improving Regulatory Transparency for New Medical Therapies Act H.R. 953/S. 524 - Comprehensive Addiction and Recovery Act of 2015 H.R. 2536/S. 1455 - Recovery Enhancement for Addiction Treatment (TREAT) Act H.R. 4435 - Comprehensive Behavioral Health Reform and Recovery Act of 2016 H.R. 4843 - Infant Plan of Safe Care Improvement Act H.R. 4978 - NAS Healthy Babies Act H.R. 4981 - Opioid Use Disorder Treatment Expansion and Modernization Act H.R. 5046 - Comprehensive Opioid Abuse Reduction Act of 2016 H.R. 5052 - Opioid Program Evaluation Act S. 1392 - Safe Prescribing of Controlled Substances Act S. 2423 - A bill making appropriations to address the heroin and opioid drug abuse epidemic for the fiscal year ending September 30, 2016, and for other purposes S. 3075 - Addiction Prevention and Responsible Opioid Practices Act
Client expense: Not reported · Firm income: $23,450
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, Veterans Affairs, Dept of (VA), White House Office
2016 · second_quarter · Pharmacy
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion, H.R. 471 "Ensuring Patient Access and Effective Drug Enforcement Act of 2015", S. 483 "Ensuring Patient Access and Effective Drug Enforcement Act of 2015", S. 524 "Comprehensive Addiction and Recovery Act of 2016"
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Pharmacy
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion, H.R. 471 "Ensuring Patient Access and Effective Drug Enforcement Act of 2015", S. 483 "Ensuring Patient Access and Effective Drug Enforcement Act of 2015", S.524 "Comprehensive Addiction and Recovery Act of 2016".
Client expense: $220,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Pharmacy
Issues related to prescription drug abuse, preferred pharmacy networks, pharmacist provider status, drug pricing and Tricare. Issues related to biosimilars, FDA repackaging and drug disposal. HR 1600 :A bill to amend title XXVII of the Public Health Service Act to limit co-payment, coinsurance, or other cost-sharing requirements applicable to prescription drugs in a specialty drug tier to the dollar amount (or its equivalent) of such requirements applicable to prescription drugs in a non-preferred brand drug tier, and for other purposes. HR 592 - Pharmacy and Medically Underserved Areas Enhancement Act S 314 - Pharmacy and Medically Underserved Areas Enhancement Act HR 244 - MAC Transparency Act S 776 - Medication Therapy Management Empowerment Act of 2015 HR 471 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015 S 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015 HR 6-Stopping Medication Abuse and Protecting Seniors Act of 2015 S 1913-Stopping Medication Abuse and Protecting Seniors Act of 2015 HR 1725-National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015 S 480-National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015 S. 524-Comprehensive Addiction and Recovery Act HR 4909-National Defense Authorization Act S 2943--National Defense Authorization Act
Client expense: $1,158,247 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of, Veterans Affairs, Dept of (VA)
2016 · second_quarter · Health Issues
Issues related to prescription drug abuse; issues related to abuse deterrent formulations; issues related to Medicaid rebates; issues related to implementation of the Affordable Care Act; HR.471- Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2016 · second_quarter · Health Issues
H.R. 471 & S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act - all provisions
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Health Issues
Issues relating to prescription drug abuse. Issues relating to incentives for tamper-resistant formulations. Issues relating to FDA approvals of new drugs and generic drugs. Issues related to the FDA Issues related to Opioids Issues relating to Medicare Part D rebates. House 21st Century Cures bill (Senate companion which includes NIH and FDA issues) H.R.471, S. 483 -Ensuring Patient Access and Effective Drug Enforcement Act of 2015 S. 524 the Comprehensive Addiction and Recovery Act and related legislation H.R. 4641 Issues relating to the labeling of generic drugs. Issues relating to CDC guidance for prescribing opioids S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act Issues relating to products containing high doses of acetaminophen. Issues relating to the labeling of generic drugs. Issues relating to removal of FDA unapproved products from the market HR 5046/S 524 - Opioid abuse legislation
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Pharmacy
(H.R. 696/S. 506) Medicare Prompt Pay Discount Exclusion,legislation to ensure more appropriate general payment amount for drugs & biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Legislation to exclude cancer drugs from sequestration cuts. HR471/S483 Ensuring Patient Access and Effective Drug Enforcement Act of 2015; Medicare Program Part B Drug Payment Model.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Alcohol and Drug Abuse
H.R. 471 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S.524 - Comprehensive Addiction and Recovery Act of 2016; H.R.953 - Comprehensive Addiction and Recovery Act of 2015; H.R. 3250 - DXM Abuse Prevention Act;
Client expense: $390,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), Office of Natl Drug Control Policy (NDCP), Office of Personnel Management (OPM), SENATE
2016 · second_quarter · Alcohol and Drug Abuse
H.R.471-Ensuring Patient Access and Effective Drug Enforcement Act of 2015 H.R.953-Comprehensive Addiction and Recovery Act of 2015 H.R.1641-Jason Simcakoski Memorial Opioid Safety Act H.R.1725-National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015 H.R.1821-Opioid Overdose Reduction Act of 2015 H.R.2298-Medicare Patient Safety and Drug Abuse Prevention Act H.R.2463-Dispose Responsibly of your Pills (DROP) Act of 2015 H.R.2536-Recovery Enhancement for Addiction Treatment (TREAT) Act H.R.2805-Heroin and Prescription Opioid Abuse Prevention, Education, and Enforcement Act of 2015 H.R.2850-Stop Overdose Stat Act of 2015 H.R.2872-Opioid Addiction Treatment Modernization Act H.R.3014-Medical Controlled Substances Transportation Act of 2015 H.R.3250-DXM Abuse Prevention Act of 2015 H.R.3537-Synthetic Drug Control Act of 2015 H.R.3677-Opioid Abuse Prevention and Treatment Act of 2015 H.R.3680-Co-Prescribing to Reduce Overdose Act of 2015 H.R.3691-Improving Treatment for Pregnant and Postpartum Women Act of 2015 H.R.3865-Cradle Act H.R.4063-Promoting Responsible Opioid Management and Incorporating Scientific Expertise Act H.R.4447-Opioid and Heroin Epidemic Emergency Supplemental Appropriations Act H.R.4499-Promoting Responsible Opioid Prescribing Act of 2016 H.R.4599-Reducing Unused Medications Act of 2016 H.R.4641-To provide for the establishment of an inter-agency task force to review, modify, and update best practices for pain management and prescribing pain medication, and for other purposes. H.R.4697-Prevevent Drug Addiction Act of 2016 S.36-Protecting Our Youth from Dangerous Synthetic Drugs Act of 2015 S.480-National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015 S.483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015 S.524-Comprehensive Addiction and Recovery Act of 2015 S.636-Increasing the Safety of Prescription Drug Use Act of 2015 S.707-Opioid Overdose Reduction Act of 2015 S.954-FDA Accountability for Public Safety Act S.1134-Heroin and Prescription Opioid Abuse Prevention, Education, and Enforcement Act of 2015 S.1327-Synthetic Abuse and Labeling of Toxic Substances (SALTS) Act S.1392-Safer Prescribing of Controlled Substances Act S.1410-Treatment and Recovery Investment Act S.1431-Prescription Drug Abuse Prevention and Treatment Act of 2015 S.1455-Recovery Enhancement for Addiction Treatment Act S.1654-Overdose Prevention Act S.1913-Stopping Medication Abuse and Protecting Seniors Act of 2015 S.2256-Co-Prescribing Saves Lives Act of 2015 S.2562-Heroin and Prescription Drug Abuse Prevention and Reduction Act S.2567-Preventing Overprescribing for Pain Act of 2016 S.2578-Reducing Unused Medications Act of 2016 S.2687-Plan of Safe Care Improvement Act
Client expense: $217,135 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Law Enforcement/Crime/Criminal Justice
H.R.159-Stop Exploitation Through Trafficking Act H.R.181-Justice for Victims of Trafficking Act H.R.246-To improve the response to victims of child sex trafficking H.R.285-Stop Advertising Victims of Exploitation (SAVE) Act H.R.350-Human Trafficking Prevention, Intervention and Recovery Act H.R.357-Human Trafficking Prevention Act H.R.398-Trafficking Awareness Training for Health Care Act H.R.460-Human Trafficking Detection Act H.R.468-Enhancing Services for Runaway and Homeless Victims for Youth Trafficking Act H.R.469-Strengthening Child Welfare Response to Trafficking Act H.R.471-Ensuring Patient Access and Effective Drug Enforcement Act of 2015 H.R.514-Human Trafficking Prioritization Act H.R.515-International Megans Law to Prevent Demand for Child Sex H.R.1854-Comprehensive Justice and Mental Health Act of 2015 H.R.1877-Mental Health First Aid Act of 2015 H.R.3014-Medical Controlled Substances Transportation Act of 2015 H.R.3537-Synthetic Drug Control Act of 2015 H.R.4365-Protecting Patient Access to Emergency Medications Act of 2016 S.178-Justice for Victims of Trafficking Act of 2015 S.483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015 S.529-Combatting Human Trafficking Act of 2015 S.623-Human Trafficking Detection Act of 2015 S.642-Human Trafficking Survivors Relief and Empowerment Act of 2015 S.711-Mental Health First Act of 2015 S.993-Comprehensive Justice and Mental Health Act of 2015 S.1446-SOAR to Health and Wellness Act of 2015 S.2932-Protecting Patient Access to Emergency Medications Act of 2016
Client expense: $217,135 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Pharmacy
Importation of prescription drugs (S. 122, H.R. 2228) Rx Pedigree (PL 113-54) Prescription Drug Monitoring Programs (S. 480, H.R. 1725) Prescription Drug Abuse - General issues related to Rx drug abuse (H.R. 471, S. 483, S. 524, H.R. 953) 21st Century Cures (H.R. 6)
Client expense: Not reported · Firm income: $80,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE